Andrew John Phillips - 05 Jun 2025 Form 4 Insider Report for MoonLake Immunotherapeutics (MLTX)

Role
Director
Signature
/s/ Matthias Bodenstedt, Attorney-in-fact for Andrew John Phillips
Issuer symbol
MLTX
Transactions as of
05 Jun 2025
Net transactions value
$0
Form type
4
Filing time
09 Jun 2025, 09:05:38 UTC
Previous filing
30 May 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"Andrew John Phillips filed Form 4 for MoonLake Immunotherapeutics (MLTX) on 09 Jun 2025."

Quick Takeaways

  • This page summarizes Andrew John Phillips's Form 4 filing for MoonLake Immunotherapeutics (MLTX).
  • 1 reported transaction and 1 derivative row are listed below.
  • Filing timestamp: 09 Jun 2025, 09:05.

What Changed

  • Previous filing in this sequence was filed on 30 May 2025.
  • Current net transaction value: $0.

Why This Matters

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Official SEC Source

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

See Original Filing

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Phillips Andrew John Director C/O MOONLAKE IMMUNOTHERAPEUTICS, DORFSTRASSE 29, ZUG, SWITZERLAND /s/ Matthias Bodenstedt, Attorney-in-fact for Andrew John Phillips 09 Jun 2025 0001921956

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MLTX Option to Buy Award $0 +6,682 $0.000000 6,682 05 Jun 2025 Class A ordinary shares, par value $0.0001 per share 6,682 $48.83 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer.

Sponsored